A20 is regulated by estrogen and A20 levels are highly increased in aggressive forms of breast cancer and involved in tamoxifen resistance (Vendrell et al. 2007), suggesting a potential role both as a marker and as a therapeutic target. This evidence concerns the gene TNFAIP3 and breast cancer.